The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
Ono Licenses Pheochromocytoma Treatment Metyrosine from Valeant
Ono Pharmaceutical announced on October 22 that it has entered into a license deal with the US-based Valeant Pharmaceuticals North America LLC, an affiliate of Valeant Pharmaceuticals International Inc. of Canada for the rights to exclusively develop and commercialize metyrosine…
To read the full story
Related Article
- Ono Files Metyrosine in Japan
April 27, 2018
BUSINESS
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
- Astellas, MRI Join Hands to Support Startups via MEDISO
June 17, 2025
- Maruishi Takes Over Bayer’s Sleep Inducer Evamyl in Japan
June 17, 2025
- Mitsubishi’s BRD4 Degrader Now in US PI/II for Solid Tumors
June 16, 2025
- Sumitomo’s Myelofibrosis Drug Earns Fast-Track Tag in US
June 16, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…